Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case–control study
- 438 Downloads
We conducted a nested case–control study to study the association between antidiabetic treatments (alone or in combination) use and fracture risk among incident type 2 Diabetes mellitus patients. We found an increased risk of bone fracture with insulin therapy compared to metformin monotherapy.
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures, to which antidiabetic therapies may contribute. We aimed to characterize the risk of fracture associated with different antidiabetic treatments as usually prescribed to T2DM patients in actual practice conditions.
A case–control study was nested within a cohort of incident T2DM patients registered in 2006–2012 in the Information System for Research Development in Primary Care (Catalan acronym, SIDIAP), a database which includes records for > 5.5 million patients in Catalonia (Spain). Each case (incident major osteoporotic fracture) was risk-set matched with up to five same-sex controls by calendar year of T2DM diagnosis and year of birth (± 10 years). Study exposure included previous use of all antidiabetic medications (alone or in combination), as dispensed in the 6 months before the index date, with metformin (MTF) monotherapy, the most commonly used drug, as a reference group (active comparator).
Data on 12,277 T2DM patients (2049 cases and 10,228 controls) were analyzed. Insulin use was associated with increased fracture risk (adjusted OR 1.63 (95% CI 1.30–2.04)), as was the combination of MTF and sulfonylurea (SU) (adjusted OR 1.29 (1.07–1.56)), compared with MTF monotherapy. Sensitivity analyses suggest possible causality for insulin therapy but not for the MTF + SU combination association. No significant association was found with any other antidiabetic medications.
Insulin monotherapy was associated with an increased fracture risk compared to MTF monotherapy in T2DM patients. Fracture risk should be taken into account when starting a glucose-lowering drug as part of T2DM treatment.
KeywordsEpidemiology Fracture risk General population Type 2 diabetes mellitus
This work has been carried out as a part of the PhD program of the Department of Medicine, Universitat Autònoma de Barcelona. CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) is an initiative from Instituto de Salud Carlos III, Spain.
The authors thank Elaine Lilly, Ph.D., for revising the manuscript for English language usage.
Compliance with ethical standards
Conflict of interest
D.P.A. declares that his department/research group has received unrestricted research grants from Amgen, Servier Laboratoires, and Bioiberica; XN has been paid by Amgen and Lilly for developing and delivering educational presentations; D.M. declares receipt of honoraria from Abbott, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Ferrer, GlaxoSmithKline, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi for consulting and presentations. ADP has been a speaker or advisory board member for Lilly, Amgen, GSK, and UCB and owns stocks of Active Life Scientific; E.L.G., B.S., M.S.A., M.P.D., and D.M.L. have no conflicts of interest.
- 6.Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM (2011) Study of osteoporotic fractures (SOF) research group; osteoporotic fractures in men (MrOS) research group; health, aging, and body composition (health ABC) research group. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184–2192CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Saito M, Morume K (2013) Bone quality in diabetes. Front Endocrinol 4:72Google Scholar
- 14.Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castaño-Betancourt MC, Estrada K, Stolk L, Oei EH, van Meurs JB, Janssen JA, Hofman A, van Leeuwen JP, Witteman JC, Pols HA, Uitterlinden AG, Klaver CC, Franco OH, Rivadeneira F (2013) High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam study. Diabetes Care 36:1619–1628CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G (2008) Diabetes outcome progression trial (ADOPT) study group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31:845–851CrossRefPubMedGoogle Scholar
- 19.Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U, Herman WH (2010) Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 95:4560–4565CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Garcia-Gil M, Hermosilla E, Prieto-Alhambra D, Fina D, Rosell M, Ramos R, Rodriguez J, Williams T, Van Staa T, Bolívar B (2011) Construction and validation of scoring a system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform Prim Care 19:135–145Google Scholar
- 30.Pagès-Castellà A, Carbonell-Abella C, Avilés FF, Alzamora M, Baena-Díez JM, Laguna DM, Nogués X, Díez-Pérez A, Prieto-Alhambra D (2012) Burden of osteoporotic fractures in primary health care in Catalonia (Spain) a population-based. BMC Musculoskelet Disord 13:79CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K (2017) Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab 19:1155–1164CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW, TECOS Study Group (2017) Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. Diabetes Obes Metab 19:78–86CrossRefPubMedGoogle Scholar
- 39.Martínez-Laguna D, Soria-Castro A, Carbonell-Abella C, Orozco-López P, Estrada-Laza P, Conesa-García A et al (2014) P-58: Estudio de incidencia de fracturas por fragilidad registradas en pacientes atendidos en la Atención Primaria de salud. Rev Osteoporos Metab Min 6:36–44Google Scholar